The 2025 BioPharma & MedTech IPO Landscape
By

With Highlights from the JP Morgan Healthcare Conference To understand the current IPO landscape of BioPharma and MedTech, let’s go straight to the data: There were 15 IPOs globally in 2024; 10 in 2023, and 25 in 2022 for MedTech companies. MedTech IPO activity peaked in 2021 with 61 companies…Read More

Read More
Key Decisions for Life Science Companies: Stay the Course or Exit via M&A?
By , , ,

This article is the fourth in a 4-part series reviewing financing solutions for the Life Science sector. Many life science companies are fortunate to reach a critical inflection point where leadership must face a decision: continue to fund growth to reach clinical milestones independently or exit via merger and acquisition….Read More

Read More
Creative Financing Approaches in Life Science
By , , ,

This article is the third in a 4-part series reviewing financing solutions for the Life Science sector. As Life Science company valuations have fluctuated significantly over the last two years, and investors have become cautious due to economic turbulence and market uncertainty, fundraising is taking longer. Equity financing has been…Read More

Read More
How to Successfully Extend the Cash Runway to Growth in Early Commercial Stage Life Science Companies
By ,

This article is the second in a 4-part series reviewing financing solutions for the Life Science sector. Life Science venture capital and private equity-funded startups are constantly chasing capital to extend operating cash runways, driving value inflection milestones such as clinical trial data and funding growth for commercial-stage entities. Understandably,…Read More

Read More

More Posts